Drug intelligence / Profile preview

Vipacal

Development stage: Unknown
Lead developer: Royal Medicalink Pharmalab
Modality: Small Molecules
Administration: Oral

Overview

Vipacal is a dietary supplement developed by Royal Medicalink Pharma (PT Royal Medicalink Pharmalab). It is formulated to support bone health and address calcium deficiencies. The product typically contains a combination of calcium (as calcium phosphate), vitamin D3 (cholecalciferol), and *Channa striata* (cork fish) extract. The inclusion of *Channa striata* extract is a characteristic of the manufacturer's product line, intended to provide additional nutritional support such as albumin. It is primarily indicated for individuals requiring increased calcium intake, including pregnant and lactating women, as well as for the prevention and treatment of osteoporosis.

Brand names: Vipacal

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Vipacal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vipacal.

Explore the full profile